Curevo Secures $110M for Advanced Shingles Vaccine Development
Curevo Vaccine raised $110 million in Series B funding to advance its shingles vaccine candidate, amezosvatein24.
The funding round was led by Medicxi, with participation from new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures, as well as existing investors4.
Amezosvatein is a non-mRNA adjuvanted subunit vaccine targeting glycoprotein E, the same antigen used in GSK's Shingrix2.
Curevo aims to match Shingrix's efficacy while improving tolerability using an optimized toll-like receptor 4 (TLR4)-based adjuvant2.
Phase 2 results showed amezosvatein's immune response was non-inferior to Shingrix, with better tolerability (7.3% vs 33.3% Grade 2 & 3 reactogenicity events)8.
The funding will support an extension of Curevo's Phase 2 program, adding 640 participants, including adults over 70, to finalize dose selection before Phase 34.
Moncef Slaoui, former Chief Scientific Advisor to Operation Warp Speed and ex-GSK vaccine executive, joins Curevo as Board Chair4.
The global shingles vaccine market is currently valued at over $4 billion, with Curevo aiming to address accessibility issues and vaccine hesitancy related to tolerability concerns6.
Sources:
2. https://www.koreabiomed.com/news/articleView.html?idxno=26948
4. https://curevovaccine.com/uncategorized/curevo-raises-110-million-to-advance-amezosvatein-shingles-vaccine/
6. https://www.biospace.com/press-releases/curevo-raises-110-million-to-advance-amezosvatein-shingles-vaccine